Amgen Inc. (NASDAQ:AMGN) Stock Holdings Raised by Thrive Wealth Management LLC

Thrive Wealth Management LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 18.7% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 2,772 shares of the medical research company’s stock after purchasing an additional 436 shares during the period. Thrive Wealth Management LLC’s holdings in Amgen were worth $788,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. BOK Financial Private Wealth Inc. bought a new stake in shares of Amgen during the 4th quarter worth about $29,000. United Community Bank bought a new stake in shares of Amgen during the 4th quarter worth about $29,000. Planned Solutions Inc. bought a new stake in shares of Amgen during the 4th quarter worth about $30,000. Delos Wealth Advisors LLC raised its position in shares of Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares in the last quarter. Finally, Hartford Financial Management Inc. raised its position in shares of Amgen by 56.9% during the 4th quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock worth $33,000 after buying an additional 41 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on AMGN shares. UBS Group boosted their price target on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Raymond James started coverage on shares of Amgen in a report on Thursday, March 28th. They issued a “market perform” rating on the stock. Mizuho boosted their target price on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Morgan Stanley boosted their target price on shares of Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a report on Friday, May 3rd. Finally, StockNews.com upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $307.35.

Amgen Stock Performance

NASDAQ:AMGN traded down $0.21 during midday trading on Friday, reaching $313.48. The stock had a trading volume of 117,587 shares, compared to its average volume of 2,763,881. Amgen Inc. has a 1-year low of $218.44 and a 1-year high of $329.72. The firm’s fifty day simple moving average is $299.67 and its 200-day simple moving average is $291.67. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. The stock has a market capitalization of $168.16 billion, a P/E ratio of 44.81, a PEG ratio of 2.83 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same period last year, the business posted $3.98 EPS. Amgen’s revenue was up 22.0% compared to the same quarter last year. On average, equities research analysts forecast that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.